Australian Commission on Safety and Quality in Health Care logo 




CARAlert data update 10

1 November 2018–31 December 2018

February 2019

Published by the Australian Commission on Safety and Quality in Health Care  
Level 5, 255 Elizabeth Street, Sydney NSW 2000

Phone: (02) 9126 3600  
Fax: (02) 9126 3613

Email: caralert@safetyandquality.gov.au   
Website: www.safetyandquality.gov.au

© Australian Commission on Safety and Quality in Health Care 2018

All material and work produced by the Australian Commission on Safety and Quality in Health Care (the Commission) is protected by copyright. The Commission reserves the right to set out the terms and conditions for the use of such material.

As far as practicable, material for which the copyright is owned by a third party will be clearly labelled. The Commission has made all reasonable efforts to ensure that this material has been reproduced in this publication with the full consent of the copyright owners.

With the exception of any material protected by a trademark, any content provided by third parties and where otherwise noted, all material presented in this publication is licensed under a [Creative Commons Attribution–NonCommercial–NoDerivatives 4.0 International licence](http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons Licence

Enquiries about the licence and any use of this publication are welcome and can be sent to [communications@safetyandquality.gov.au](mailto:communications@safetyandquality.gov.au).

The Commission’s preference is that you attribute this publication (and any material sourced from it) using the following citation:

Australian Commission on Safety and Quality in Health Care. CARAlert update 10: 1 November 2018–31 December 2018. Sydney: ACSQHC; 2019

**Disclaimer**

The content of this document is published in good faith by the Commission for information purposes. The document is not intended to provide guidance on particular healthcare choices. You should contact your healthcare provider for information or advice on particular healthcare choices.

The Commission does not accept any legal liability for any injury, loss or damage incurred by the use of, or reliance on, this document.

## Summary

This data update is one of a [series](https://www.safetyandquality.gov.au/antimicrobial-use-and-resistance-in-australia/what-is-aura/national-alert-system-for-critical-antimicrobial-resistances-caralert/) to provide regular data updates and six-monthly detailed analyses of data submitted to the National Alert System for Critical Antimicrobial Resistances (CARAlert).

Analyses presented in this update relate to 254 isolates collected from 1 November 2018 to 31 December 2018, where the results were reported to CARAlert by 31 January 2019. From the commencement of CARAlert (17 March 2016) to 31 December 2018, 3,685 results from 97 originating laboratories across Australia were entered into the CARAlert system.

See [Appendix 1](#_Appendix_1) for information about CARAlert and its contribution to the Antimicrobial Use and Resistance in Australia (AURA) Surveillance System.

### Data highlights

[Figure 1](#_Figure_1:_Critical) and [Table 1](#_Table_2:_Number) show the number and distribution of critical antimicrobial resistance (CAR) isolates, by state and territory.

Compared to the previous two-month reporting period, multidrug-resistant *Shigella* has increased 125% (*n* = 18) and carbapenemase-producing Enterobacterales (CPE), either alone (130) or with ribosomal methyltransferases (4) increased by 18% (*n*= 134). Azithromycin non-susceptible (low-level resistance, MIC ≤ 256 mg/L) *Neisseria gonorrhoeae* decreased by 17% (*n*= 72). CPE and azithromycin non-susceptible (low-level resistance, MIC ≤ 256 mg/L) *Neisseria gonorrhoeae* resistances were the most commonly reported (81%) of all CARs. The great majority (88%) of all reported cases were from New South Wales, Victoria and Queensland.

[Figure 2](#_Figure_2:_Critical) shows the CARs reported by species and month, 1 November 2018 to 31 December 2018.

[Figures 3](#_Figure_3:_Carbapenemase-producing) to 5 show details of carbapenemase type and the species of CPE, by state and territory, 1 November 2018 to 31 December 2018. IMP (64.9%), NDM (25.4%) and OXA-48-like (9.0%) types accounted for 97.0% of all CPE reported during this period, with 90.3% from New South Wales, Victoria and Queensland. Forty-nine percent of CPE were from clinical specimens, although differences were seen between states and territories.

There continues to be an increase in the number of NDM types reported nationally, although differences were seen between states and territories. Over 40% of reported NDM types were from Queensland, where a four-fold increase from the previous two-month period was seen. In Victoria and Queensland, NDM types represented one third of all CPE reported from clinical specimens.

Nineteen public hospitals had more than two notifications of the same CPE type during this period. These institutions were in New South Wales (9), Queensland (4), Victoria (4), Western Australia (1) and the Australian Capital Territory (1).

An ongoing outbreak of CPE with IMP type is in one public hospital in Victoria, where there is also local surveillance of CPE. This institution contributed 86% (31/36) of CPE with IMP types for that state.

The distribution of ceftriaxone or azithromycin non-susceptible *N. gonorrhoeae*, by state and territory, is shown in [Figure 6](#_Figure_6:_Neisseria). There was one ceftriaxone non-susceptible *N. gonorrhoeae* confirmed, collected in December 2018 from a patient residing in Queensland.

### Implications of key findings and response

The findings regarding CPE highlight the importance of implementation of the Commission’s [2017 CPE control guidelines](https://www.safetyandquality.gov.au/our-work/healthcare-associated-infection/cpe-guide/).

The findings regarding azithromycin non-susceptible *N. gonorrhoeae* highlight the importance of state and territory sexually transmitted infection control and prevention programs.

Each state and territory health department has designated officers who have access to the CARAlert database to enable detailed review of CARs reported for their jurisdiction, including the name of the public hospital where a patient with a confirmed CAR was cared for. This information assists states and territories to determine whether infection prevention and control and/or follow-up response action is required.

The Commission has been funded by the Australian Government Department of Health to collaborate with all states and territories, the Communicable Diseases Network of Australia and other relevant experts to develop a model for an antimicrobial resistance (AMR) surveillance and outbreak response network. CARAlert will be one of the data sources to inform AMR outbreak responses.

A review of CARs reported to CARAlert was completed in 2018. The review assessed the resistances and species that are currently reported to CARAlert to determine that they continue to be priorities, and identified additional CARs that should be captured by CARAlert.

System changes to accommodate reporting of four new CARs – transferrable resistance to colistin in Enterobacterales, carbapenemase-producing *Acinetobacter baumannii* complex, carbapenemase-producing *Pseudomonas aeruginosa* and *Candida auris* – are expected to be completed so that reporting can commence in the coming months.

### Data

#### Table 1: Number of critical antimicrobial resistance isolates, by state and territory, 1 November 2018 to 31 December 2018

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Critical antimicrobial resistance | NSW | Vic | Qld | SA | WA | Tas | NT | ACT | 1 November – 31 December | | | 1 January – 31 December | | |
| **2018** | **2017** | **Relative change\*** | **2018** | **2017** | **Relative change\*** |
| Carbapenemase-producing Enterobacterales | 34 | 49 | 34 | 1 | 8 | 2 | 0 | 2 | 130 | 69 | 88.4% | 603 | 527 | 14.4% |
| Azithromycin non-susceptible (LLR < 256 mg/L) *Neisseria gonorrhoeae* | 32 | 30 | 5 | 0 | 0 | 0 | 0 | 5 | 72 | 75 | -4.0% | 516 | 730 | -29.3% |
| Daptomycin non-susceptible *Staphylococcus aureus* | 1 | 11 | 1 | 0 | 8 | 0 | 0 | 0 | 21 | 21 | 0.0% | 122 | 121 | 0.8% |
| Carbapenemase and ribosomal methyltransferase-producing Enterobacterales | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 4 | 8 | -50.0% | 29 | 34 | -14.7% |
| Ceftriaxone non-susceptible *Salmonella* species | 1 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 5 | 8 | -37.5% | 51 | 38 | 34.2% |
| Ribosomal methyltransferase-producing Enterobacterales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | -100.0% | 10 | 24 | -58.3% |
| Multidrug-resistant *Shigella* species | 6 | 0 | 10 | 2 | 0 | 0 | 0 | 0 | 18 | 14 | 28.6% | 64 | 32 | 100.0% |
| Linezolid non-susceptible *Enterococcus* species | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0.0% | 14 | 5 | 180.0% |
| Multidrug-resistant *Mycobacterium tuberculosis* | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 3 | -66.7% | 19 | 20 | -5.0% |
| Ceftriaxone non-susceptible *Neisseria gonorrhoeae* | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | – | 3 | 0 | – |
| Azithromycin non-susceptible (HLR > 256 mg/L) *Neisseria gonorrhoeae* | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | 7 | 4 | 75.0% |
| Ceftriaxone non-susceptible and azithromycin resistant (HLR > 256 mg/L) *Neisseria gonorrhoeae* | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | 2 | 0 | – |
| Ceftriaxone non-susceptible and azithromycin resistant (LLR < 256 mg/L) *Neisseria gonorrhoeae* | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | 1 | 0 | – |
| Linezolid non-susceptible *Staphylococcus aureus* | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | 1 | 1 | 0.0% |
| Daptomycin and vancomycin non-susceptible *Staphylococcus aureus* | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | – | 1 | 0 | – |
| **Total (reported by 31 January 2019)** | **74** | **93** | **56** | **5** | **16** | **3** | **0** | **7** | **254** | **205** | **23.9%** | **1,443** | **1,536** | **-6.1%%** |

HLR = high-level resistance; LLR = low-level resistance; – = not applicable

\* Relative change = absolute change between period in 2017 and same period in 2018, expressed as a percentage of 2017 base

#### Figure 1: Critical antimicrobial resistances (CARs), number and distribution reported nationally, and by state and territory, 1 January 2018 to 31 December 2018



Figure 1 (continued): Critical antimicrobial resistances (CARs), number and distribution reported nationally, and by state and territory, 1 January 2018 to 31 December 2018

Figure 2: Critical antimicrobial resistances, number reported by species and month, year on year, 1 January 2017 to 31 December 2018

**D.** *Neisseria gonorrhoeae* – azithromycin non-susceptible (high level resistance) or ceftriaxone non-susceptible

**B.** Enterobacterales – ribosomal methyltransferase-producing

**C.** *Neisseria gonorrhoeae* – azithromycin non-susceptible (low level resistance)

**A.** Enterobacterales – carbapenemase-producing

Bars: number of each CAR type reported for each organism for 2018 (January to December)

Lines: number of each CAR type reported for each organism for 2017 (January to December)

AZI (LLR) = azithromycin non-susceptible, low level resistance (LLR, MIC < 256 mg/L) Neisseria gonorrhoeae; AZI (HLR) = HLR =azithromycin non-susceptible, high level resistance (HLR, MIC > 256 mg/L) Neisseria gonorrhoeae; CPE =carbapenemase-producing Enterobacterales; CPE+RMT = carbapenemase- and ribosomal methyltransferase-producing Enterobacterales; CTR NGON = ceftriaxone non-susceptible Neisseria gonorrhoeae; CTR+AZI (HLR) = ceftriaxone non-susceptible and azithromycin non-susceptible, high level resistance (HLR, MIC > 256 mg/L) Neisseria gonorrhoeae; CTR+AZI (LLR) = ceftriaxone non-susceptible and azithromycin non-susceptible, low level resistance (LLR, MIC < 256 mg/L) Neisseria gonorrhoeae; RMT = ribosomal methyltransferase-producing Enterobacterales

Figure 2 (continued): Critical antimicrobial resistances, number reported by species and month, year on year, 1 January 2017 to 31 December 2018

**G.** *Shigella* – multidrug-resistant

**E.** *Staphylococcus aureus*

**F.** *Salmonella* – ceftriaxone non-susceptible

**I.** *Mycobacterium tuberculosis* – multidrug resistant

**H.** *Enterococcus* species – linezolid non-susceptible

Bars: number of each CAR type reported for each organism for 2018 (January to December)

Lines: number of each CAR type reported for each organism for 2017 (January to December)

DAP = daptomycin non-susceptible Staphylococcus aureus; LNZ = linezolid non-susceptible Staphylococcus aureus; DAP+VAN = daptomycin and vancomycin non-susceptible Staphylococcus aureus

### Carbapenemase-producing Enterobacterales type, by state and territory

#### Figure 3: Carbapenemase-producing Enterobacterales\*, by carbapenemase type and specimen type, number reported by state and territory, 1 November 2018 to 31 December 2018.

\* Carbapenemase-producing Enterobacterales (n = 130), carbapenemase- and ribosomal methyltransferase-producing Enterobacterales (n = 4)

#### Figure 4: Two–year trend data for the top four carbapenemase types, by state and territory andnationally, 1 January 2017 to 31 December 2018

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Type** | **NSW** | **Vic** | **Qld** | **SA** | **WA** | **Tas** | **NT** | **ACT** | **Australia** |
| IMP |  |  |  |  |  |  |  |  |  |
| NDM |  |  |  |  |  |  |  |  |  |
| OXA-48-like |  |  |  |  |  |  |  |  |  |
| KPC |  |  |  |  |  |  |  |  |  |
| All types |  |  |  |  |  |  |  |  |  |

Line graphs represent three-month moving average for the period 1 January 2017 to 31 December 2018, for each type, where maximum monthly average was greater than one.

Straight line in cell = no carbapenemase type for that state or territory during the reporting period

Blank cell = maximum monthly average was one or less

### Carbapenemase-producing Enterobacterales by species and carbapenemase type

#### Figure 5: Carbapenemase-producing Enterobacterales, number reported by (A) species and (B) carbapenemase type, 1 November 2018 and 31 December 2018

**A.** **Species (*n*) by carbapenemase type**

**B.** **Carbapenemase type (*n*) by species**

\* Carbapenemase-producing Enterobacterales (n = 130), carbapenemase- and ribosomal methyltransferase-producing Enterobacterales (n = 4)

## *Neisseria gonorrhoeae* by state and territory

#### Figure 6: **Neisseria gonorrhoeae, number reported by state and territory, and month of collection\*,** 1 November 2018 and 31 December 2018

\* Where state and territory of residence is unknown, the state of the originating laboratory has been assigned

### Appendix 1

## About CARAlert

CARAlert is a key component of the Antimicrobial Use and Resistance in Australia (AURA) Surveillance System. CARAlert was established by the Australian Commission on Safety and Quality in Health Care (the Commission) in March 2016.

The AURA Surveillance System, coordinated by the Commission, provides essential information to develop and implement strategies to prevent and contain antimicrobial resistance (AMR) in human health and improve antimicrobial use across the acute and community healthcare settings. AURA also supports the National Safety and Quality Health Service (NSQHS) Standard Preventing and Controlling Healthcare-Associated Infection and Australia’s National Antimicrobial Resistance Strategy (2015–2019). Funding for AURA is provided by the Australian Government Department of Health and state and territory health departments.

Critical antimicrobial resistances (CARs) are resistance mechanisms known to be a serious threat to the effectiveness of last-line antimicrobial agents. CARs can result in significant morbidity and mortality.

The CARs reported under CARAlert are listed in Table 2. The CARs were drawn from the list of high-priority organisms and antimicrobials which are the focus of the AURA Surveillance System.[[1]](#footnote-1)

**Table 2: List of critical antimicrobial resistances reported to CARAlert**

|  |  |
| --- | --- |
| Species | Critical Resistance |
| Enterobacterales | Carbapenemase-producing, and/or  ribosomal methyltransferase-producing |
| *Enterococcus* species | Linezolid non-susceptible |
| *Mycobacterium tuberculosis* | Multidrug-resistant – resistant to at least rifampicin and isoniazid |
| *Neisseria gonorrhoeae* | Ceftriaxone or azithromycin non-susceptible |
| *Salmonella* species | Ceftriaxone non-susceptible |
| *Shigella* species | Multidrug-resistant |
| *Staphylococcus aureus* | Vancomycin, linezolid or daptomycin non-susceptible |
| *Streptococcus pyogenes* | Penicillin reduced susceptibility |

Note: Enterobacterales (new taxonomy)

The CARAlert system is based on the following routine processes used by pathology laboratories for identifying and confirming potential CARs:

* Collection and routine testing – the isolate is collected from the patient and sent to the originating laboratory for routine testing
* Confirmation – if the originating laboratory suspects that the isolate is a CAR, it sends the isolate to a confirming laboratory that has the capacity to confirm the CAR
* Submission to the CARAlert system – the confirming laboratory advises the originating laboratory of the result of the test, and the originating laboratory reports back to the health service that cared for the patient from whom the specimen was collected; the confirming laboratory then submits the details of the resistance and organism into the secure CARAlert web portal.



Level 5, 255 Elizabeth Street, Sydney NSW 2000  
GPO Box 5480, Sydney NSW 2001

Phone: (02) 9126 3600   
Fax: (02) 9126 3613

Email: mail@safetyandquality.gov.au   
Website: www.safetyandquality.gov.au

1. Australian Commission on Safety and Quality in Health Care (ACSQHC). AURA 2017: Second Australian report on antimicrobial use and resistance in human health. Sydney: ACSQHC; 2017. [↑](#footnote-ref-1)